Dr. Joerns is a native Texan who received his initial medical training at the University of Texas McGovern Medical School in Houston Texas. Initially drawn to the broadness of internal medical training he completed his residency at The Barnes Jewish Hospital / Washington University School of Medicine in St. Louis. There he developed an interest in critical care medicine, acutely caring for the sickest patients, and enjoyed early exposure to advanced therapies for heart and lung diseases, including transplantation. Fellowship in pulmonary and critical care medicine followed at Yale school of medicine.
At Yale he further refined his clinical skills and experience and spent time in the lab of Jon Koff M.D. working on potential therapies for respiratory viral infections. His current areas of focus revolve around the care of lung transplant patients, investigations into donor–directed antibodies post-transplant and therapies for severe ARDS. He and his family have been delighted to have the chance to return to his native Texas and join the fantastic team that built the UTSW lung transplant program and pulmonary division into national leaders.
Dr. Joerns is a board certified Internist, Pulmonologist and Intensivist practicing with the UTSW lung transplant program. His major interests outside of medicine include travel, backpacking, and better getting to know Dallas.
- Medical School
- UT Health Science Center McGovern Medical School (2012)
- Washington University Barnes Jewish Hospital/ St. Louis Children's Hospital Consortium Program (2015), Internal Medicine
- Yale-New Haven Medical Center (2018), Pulmonary Diseases & Critical Care Medicine
- Acute Respiratory Distress Syndrome (ARDS) or ?Acute Lung Injury? therapies including ECMO and certain protective ventilator techniques
- Bedside ultrasound to aid in diagnosis and procedural guidance
- Better identifying and treating disease causing antibodies after transplantation
- Quality improvement in thoracic organ transplantation
- Teaching trainees how to approach Lung Transplant patients
- Respiratory syncytial virus activates epidermal growth factor receptor to suppress interferon regulatory factor 1-dependent interferon-lambda and antiviral defense in airway epithelium.
- Kalinowski A, Galen BT, Ueki IF, Sun Y, Mulenos A, Osafo-Addo A, Clark B, Joerns J, Liu W, Nadel JA, Dela Cruz CS, Koff JL, Mucosal Immunol 2018 05 11 3 958-967
- American Society of Transplantation (2018)
- ELSO Extra Corporeal Life Support Organization (2018)
- International Society of Heart-Lung Transplantation (2018)
- American Thoracic Society (2015)